Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects

A pharmacological mixture suited for daily treatment of chronic pain, comprising a combination of:

• (a) a first drug which is a tricyclo-alkylamine compound or a prodrug, salt, isomer, analog, or derivative thereof, and which is pharmaceutically acceptable, and which suppresses activity at NMDA-type glutamate receptors;
• and,
• (b) a second drug which stimulates activity at α2 adrenergic receptors,
• wherein the first and second drugs are present in the mixture at relative concentrations which, when combined, can be administered to a mammal suffering from chronic pain, in a manner which will provide chronic pain relief which lasts longer than comparable pain relief that can be provided by either drug alone, and wherein the combination causes lower levels of adverse side effects than either drug administered by itself would cause at a dosage which provides comparable short-term relief from chronic pain.

A pharmacological article of manufacture comprising a unitary dosage formulation which contains:

• (a) a first drug which is a tricyclo-alkylamine compound or a prodrug, salt, isomer, analog, or derivative thereof, and which suppresses activity at NMDA-type glutamate receptors;
• and,
• (b) a second drug which stimulates activity at alpha-2 adrenergic receptors,
• wherein the first and second drugs are combined with each other in the unitary dosage formulation in dosages which, when combined, provide synergistic and therapeutically effective relief from chronic pain, wherein such relief lasts longer than comparable pain relief provided by either drug alone, and wherein the combination causes lower levels of adverse side effects than either drug administered by itself would cause at a dosage which provides comparable short-term relief from chronic pain.